3区 · 医学
Article
作者: Ork, Britini L ; Hensley, Lisa E ; Johnson, Joshua C ; Bohorov, Ognian ; Mollura, Daniel J ; Bartos, Christopher J ; Zeitlin, Larry ; Keith, Lauren ; Solomon, Jeffrey ; Bohorova, Natasha ; Huzella, Louis ; Jahrling, Peter B ; Johnson, Reed F ; Sun, Jiusong ; Zhu, Quan ; Velasco, Jesus ; Whaley, Kevin J ; Qin, Jing ; Marasco, Wayne A ; Kim, Do H ; Bagci, Ulas ; Olinger, Gene G ; Pettitt, James ; Holbrook, Michael R ; Goodman, Charles ; Paulty, Michael H ; Baric, Ralph S ; Tang, Xianchun ; Oberlander, Nicholas
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was identified in 2012 as the causative agent of a severe, lethal respiratory disease occurring across several countries in the Middle East. To date there have been over 1600 laboratory confirmed cases of MERS-CoV in 26 countries with a case fatality rate of 36%. Given the endemic region, it is possible that MERS-CoV could spread during the annual Hajj pilgrimage, necessitating countermeasure development. In this report, we describe the clinical and radiographic changes of rhesus monkeys following infection with 5×10(6) PFU MERS-CoV Jordan-n3/2012. Two groups of NHPs were treated with either a human anti-MERS monoclonal antibody 3B11-N or E410-N, an anti-HIV antibody. MERS-CoV Jordan-n3/2012 infection resulted in quantifiable changes by computed tomography, but limited other clinical signs of disease. 3B11-N treated subjects developed significantly reduced lung pathology when compared to infected, untreated subjects, indicating that this antibody may be a suitable MERS-CoV treatment.